Invesco BulletShares 2028 Corporate Bond ETF
BSCS
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Bonds
- Address
- 11 Greenway Plaza, Suite 1000 Houston TX United States of America 77046
- IPO Date
- Aug 9, 2018
- CIK
- 0001657201
- Website
- invesco.com
- Similar Companies
- Business
- Invesco BulletShares 2028 Corporate Bond ETF (BSCS) is an exchange-traded fund that seeks to track the performance, before fees and expenses, of the Invesco BulletShares USD Corporate Bond 2028 Index. The fund invests at least 80% of its total assets in U.S. dollar-denominated, investment-grade corporate bonds with effective maturities in 2028; these include securities rated BBB- or higher by S&P and Fitch or Baa3 or higher by Moody's; the portfolio employs a representative sampling methodology rather than full replication of the index; and the fund rebalances monthly while maintaining approximately 433 holdings as of late 2025. Launched on August 9, 2018, and domiciled in the United States with primary listing on Nasdaq, BSCS operates within the target-maturity bond ETF segment, targeting investors seeking defined-maturity exposure to corporate fixed income; its geographic allocation emphasizes U.S. issuers at 83.18%, with additional exposure to Canada, Japan, the United Kingdom, Ireland, Switzerland, Spain, Norway, and the Netherlands; and sector weights feature financials (23.12%), health care (13.19%), information technology (11.22%), industrials (10.21%), and others. The fund maintains a total expense ratio of 0.10%, an effective duration of 2.40 years, and a 30-day SEC yield of 4.02% as of September 30, 2025; top holdings include CVS Health Corp 4.30% due March 25, 2028 (1.27%), The Cigna Group 4.38% due October 15, 2028 (0.99%), and Amgen Inc. 5.15% due March 2, 2028 (0.98%); and it plans to terminate on or about December 15, 2028, distributing proceeds primarily from maturing bonds and transitioning to cash equivalents in its final year. In recent developments, BSCS has sustained steady assets under management exceeding $2.75 billion, with notable institutional interest including Bank of America Corp DE increasing its position by 15,676 shares; regular monthly dividend distributions continued, such as the ex-dividend date of August 18, 2025, at $0.07935 per share; and the fund reported year-to-date NAV performance of 5.60% and one-year returns of 4.63% as of September 30, 2025, amid a stable operating environment without major acquisitions, partnerships, or strategic shifts reported in the last 1-2 years.